More on BLTE

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-182.1% Growth)
- Ratings (10.0 Score)
- Holders

Upcoming Events

- Earnings (11/17/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Belite Bio (NQ:BLTE)
Delayed: 142.78 -9.84 (6.45%)
Prev. Close $152.62  
Open$152.62 
52 Wk High$ 
52 Wk Low$ 
Day High$152.62 
Day Low$141.62 
P/E N/A  
EPS$ 
Volume193,839 

Friends, Peers and Foes (?): LOT, VIOT, YRD, FPAFY, FPC (more...)

Oct 15, 2026 07:09 AM H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)
Oct 14, 2026 04:03 PM Belite Bio files for tinlarebant approval in three new markets
Oct 14, 2026 04:00 PM Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Oct 5, 2026 07:28 PM Form 4 BELITE BIO, INC For: Oct 01 Filed by: Scholl Hendrik Peter
Oct 1, 2026 06:04 PM Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter
Oct 1, 2026 08:00 AM Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Sep 28, 2026 08:00 PM Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Sep 9, 2026 07:25 AM Belite Bio, Inc, ADR (BLTE) PT Raised to $245 at H.C. Wainwright
Sep 9, 2026 06:54 AM Belite Bio, Inc, ADR (BLTE) PT Raised to $234 at Mizuho
Sep 8, 2026 06:00 AM Belite Bio files Japan drug application for Stargardt disease treatment
View All Articles

Entities mentioned with BLTE

View All Entities